nach oben

Erschienen in:

04.07.2021 | ß-Blockers

Heart failure and atrial fibrillation: new concepts in pathophysiology, management, and future directions

verfasst von: Grigorios Tsigkas, Anastasios Apostolos, Stefanos Despotopoulos, Georgios Vasilagkos, Eleftherios Kallergis, Georgios Leventopoulos, Virginia Mplani, Periklis Davlouros

Erschienen in: Heart Failure Reviews | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

A bidirectional pathophysiological link connects heart failure and atrial fibrillation, creating a frequent and challenging comorbidity, which includes neurohormonal hyperactivation, fibrosis development, and electrophysiologic remodeling, while they share mutual risk factors. Management for these devastating comorbidities includes most of the established treatment measures for heart failure as well as rhythm or rate control and anticoagulation mostly for atrial fibrillation, which can be achieved with either pharmaceutical or non-pharmaceutical approaches. The current manuscript aims to review the existing literature regarding the underlying pathophysiology, to present the novel trends of treatment, and to predict the future perspective of these two linked diseases with the numerous unanswered questions.

Stafylas P, Farmakis D, Kourlaba G et al (2017) The heart failure pandemic: the clinical and economic burden in Greece. Int J Cardiol 227:923–929. https://doi.org/10.1016/j.ijcard.2016.10.042CrossRefPubMed

Cha YM, Redfield MM, Shen WK, Gersh BJ (2004) Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 109:2839–2843. https://doi.org/10.1161/01.CIR.0000132470.78896.A8CrossRefPubMed

Maisel WH, Stevenson LW (2003) Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91:2D-8D. https://doi.org/10.1016/s0002-9149(02)03373-8CrossRefPubMed

Swedberg K, Olsson LG, Charlesworth A et al (2005) Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 26:1303–1308. https://doi.org/10.1093/eurheartj/ehi166CrossRefPubMed

Olsson LG, Swedberg K, Ducharme A et al (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47:1997–2004. https://doi.org/10.1016/j.jacc.2006.01.060CrossRefPubMed

Solti F, Vecsey T, Kékesi V, Juhász-Nagy A (1989) The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res 23:882–886. https://doi.org/10.1093/cvr/23.10.882CrossRefPubMed

Dzau VJ, Colucci WS, Hollenberg NK, Williams GH (1981) Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 63:645–651. https://doi.org/10.1161/01.cir.63.3.645CrossRefPubMed

Triposkiadis F, Xanthopoulos A, Parissis J et al (2020) Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. Heart Fail Rev. https://doi.org/10.1007/s10741-020-09987-zCrossRefPubMedPubMedCentral

Shen MJ, Choi E-K, Tan AY et al (2011) Neural mechanisms of atrial arrhythmias. Nat Rev Cardiol 9:30–39. https://doi.org/10.1038/nrcardio.2011.139CrossRefPubMed

10.

Zankov DP, Omatsu-Kanbe M, Isono T et al (2006) Angiotensin II potentiates the slow component of delayed rectifier K+ current via the AT1 receptor in guinea pig atrial myocytes. Circulation 113:1278–1286. https://doi.org/10.1161/CIRCULATIONAHA.104.530592CrossRefPubMed

11.

Hu YF, Chen YJ, Lin YJ, Chen S-A (2015) Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol 12:230–243. https://doi.org/10.1038/nrcardio.2015.2CrossRefPubMed

12.

Gopinathannair R, Etheridge SP, Marchlinski FE et al (2015) Arrhythmia-induced cardiomyopathies: mechanisms, recognition, and management. J Am Coll Cardiol 66:1714–1728. https://doi.org/10.1016/j.jacc.2015.08.038CrossRefPubMedPubMedCentral

13.

Kareti KR, Chiong JR, Hsu SS, Miller AB (2005) Congestive heart failure and atrial fibrillation: rhythm versus rate control. J Card Fail 11:164–172. https://doi.org/10.1016/j.cardfail.2004.09.011CrossRefPubMed

14.

Swedberg K, Zannad F, McMurray JJV et al (2012) Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 59:1598–1603. https://doi.org/10.1016/j.jacc.2011.11.063CrossRefPubMed

15.

McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004. https://doi.org/10.1056/NEJMoa1409077CrossRefPubMed

16.

Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution. Eur J Heart Fail 18:891–975. https://doi.org/10.1002/ejhf.592CrossRefPubMed

17.

Martin RIR, Pogoryelova O, Koref MS et al (2014) Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart 100:1506–1510. https://doi.org/10.1136/heartjnl-2014-305482CrossRefPubMed

18.

Padeletti L, Musilli N, Porciani MC et al (2004) Atrial fibrillation and cardiac resynchronization therapy: the MASCOT study. Eur Eur pacing, arrhythmias, Card Electrophysiol J Work groups Card pacing, arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol 5(Suppl 1):S49-54. https://doi.org/10.1016/j.eupc.2004.07.007CrossRef

19.

Stone GW, Lindenfeld J, Abraham WT et al (2018) Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379:2307–2318. https://doi.org/10.1056/NEJMoa1806640CrossRefPubMed

20.

Barrio-Lopez MT, Ruiz-Canela M, Ramos P et al (2020) PREvention of recurrent arrhythmias with Mediterranean diet (PREDIMAR) study in patients with atrial fibrillation: rationale, design and methods. Am Heart J 220:127–136. https://doi.org/10.1016/j.ahj.2019.10.009CrossRefPubMed

21.

Lavie CJ, Pandey A, Lau DH et al (2017) Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. J Am Coll Cardiol 70:2022–2035. https://doi.org/10.1016/j.jacc.2017.09.002CrossRefPubMed

22.

Voskoboinik A, Prabhu S, Ling L-H et al (2016) Alcohol and atrial fibrillation: a sobering review. J Am Coll Cardiol 68:2567–2576. https://doi.org/10.1016/j.jacc.2016.08.074CrossRefPubMed

23.

Zhu W, Guo L, Hong K (2016) Relationship between smoking and adverse outcomes in patients with atrial fibrillation: a meta-analysis and systematic review. Int J Cardiol 222:289–294. https://doi.org/10.1016/j.ijcard.2016.07.220CrossRefPubMed

24.

Hindricks G, Potpara T, Dagres N et al (2020) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa612CrossRefPubMedPubMedCentral

25.

Sartipy U, Dahlström U, Fu M, Lund LH (2017) Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 5:565–574. https://doi.org/10.1016/j.jchf.2017.05.001CrossRefPubMed

26.

Li SJ, Sartipy U, Lund LH et al (2015) Prognostic significance of resting heart rate and use of β-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish Heart Failure Registry. Circ Heart Fail 8:871–879. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002285CrossRefPubMed

27.

Mareev Y, Cleland JGF (2015) Should β-blockers be used in patients with heart failure and atrial fibrillation? Clin Ther 37:2215–2224. https://doi.org/10.1016/j.clinthera.2015.08.017CrossRefPubMed

28.

January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:e1-76. https://doi.org/10.1016/j.jacc.2014.03.022CrossRefPubMed

29.

Kotecha D, Flather MD, Altman DG et al (2017) Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol 69:2885–2896. https://doi.org/10.1016/j.jacc.2017.04.001CrossRefPubMed

30.

Kotecha D, Holmes J, Krum H et al (2014) Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet (London, England) 384:2235–2243. https://doi.org/10.1016/S0140-6736(14)61373-8CrossRef

31.

Rienstra M, Damman K, Mulder BA et al (2013) Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail 1:21–28. https://doi.org/10.1016/j.jchf.2012.09.002CrossRefPubMed

32.

Filippatos G, Farmakis D (2017) How to use beta-blockers in heart failure with reduced ejection fraction and atrial fibrillation. J Am Coll Cardiol 69:2897–2900CrossRef

33.

Nielsen PB, Larsen TB, Gorst-Rasmussen A et al (2016) β-Blockers in atrial fibrillation patients with or without heart failure: association with mortality in a nationwide cohort study. Circ Heart Fail 9:e002597. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002597CrossRefPubMed

34.

Singh BN, Singh SN, Reda DJ et al (2005) Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352:1861–1872. https://doi.org/10.1056/NEJMoa041705CrossRefPubMed

35.

Rich MW, McSherry F, Williford WO, Yusuf S (2001) Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 38:806–813. https://doi.org/10.1016/s0735-1097(01)01442-5CrossRefPubMed

36.

Lopes RD, Rordorf R, De Ferrari GM et al (2018) Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol 71:1063–1074. https://doi.org/10.1016/j.jacc.2017.12.060CrossRefPubMed

37.

Gasparini M, Leclercq C, Lunati M et al (2013) Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail 1:500–507. https://doi.org/10.1016/j.jchf.2013.06.003CrossRefPubMed

38.

Gottlieb SS, Kukin ML, Medina N et al (1990) Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure. Circulation 81:860–864. https://doi.org/10.1161/01.cir.81.3.860CrossRefPubMed

39.

Køber L, Torp-Pedersen C, McMurray JJV et al (2008) Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358:2678–2687. https://doi.org/10.1056/NEJMoa0800456CrossRefPubMed

40.

Torp-Pedersen C, Møller M, Bloch-Thomsen PE et al (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 341:857–865. https://doi.org/10.1056/NEJM199909163411201CrossRefPubMed

41.

Singh BN (2002) Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. Heart Fail Rev 7:285–300. https://doi.org/10.1023/a:1020001912248CrossRefPubMed

42.

Grubb A, Mentz RJ (2020) Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. Expert Rev Cardiovasc Ther 18:85–101. https://doi.org/10.1080/14779072.2020.1732210CrossRefPubMed

43.

Heijman J, Voigt N, Abu-Taha IH, Dobrev D (2013) Rhythm control of atrial fibrillation in heart failure. Heart Fail Clin 9:407–15, vii–viii. https://doi.org/10.1016/j.hfc.2013.06.001

44.

Imamura T, Kinugawa K (2020) Novel rate control strategy with landiolol in patients with cardiac dysfunction and atrial fibrillation. ESC Hear Fail 7:2208–2213. https://doi.org/10.1002/ehf2.12879CrossRef

45.

Neuberger H-R, Mewis C, van Veldhuisen DJ et al (2007) Management of atrial fibrillation in patients with heart failure. Eur Heart J 28:2568–2577. https://doi.org/10.1093/eurheartj/ehm341CrossRefPubMed

46.

Matsui Y, Suzuki A, Shiga T et al (2019) Effects of intravenous landiolol on heart rate and outcomes in patients with atrial tachyarrhythmias and acute decompensated heart failure: a single-center experience. Drugs-real world outcomes 6:19–26. https://doi.org/10.1007/s40801-019-0149-1CrossRefPubMedPubMedCentral

47.

Roy D, Talajic M, Nattel S et al (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:2667–2677. https://doi.org/10.1056/NEJMoa0708789CrossRefPubMed

48.

Corley SD, Epstein AE, DiMarco JP et al (2004) Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 109:1509–1513. https://doi.org/10.1161/01.CIR.0000121736.16643.11CrossRefPubMed

49.

Marrouche NF, Brachmann J, Andresen D et al (2018) Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378:417–427. https://doi.org/10.1056/NEJMoa1707855CrossRefPubMed

50.

Turagam MK, Garg J, Whang W et al (2019) Catheter ablation of atrial fibrillation in patients with heart failure: a meta-analysis of randomized controlled trials. Ann Intern Med 170:41–50. https://doi.org/10.7326/M18-0992CrossRefPubMed

51.

Lip GYH, Heinzel FR, Gaita F et al (2015) European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Eur J Heart Fail 17:848–874. https://doi.org/10.1002/ejhf.338CrossRefPubMed

52.

Guimarães HP, Lopes RD, de Barros E, Silva PGM et al (2020) Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. https://doi.org/10.1056/NEJMoa2029603CrossRefPubMed

53.

Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (London, England) 383:955–962. https://doi.org/10.1016/S0140-6736(13)62343-0CrossRef

54.

Tzeis S, Savvari P, Skiadas I et al (2020) Right drug, wrong dosage: insights from the PAVE-AF antithrombotic study in older patients with atrial fibrillation. J Thromb Thrombolysis. https://doi.org/10.1007/s11239-020-02167-8CrossRefPubMedCentral

55.

Sardar P, Chatterjee S, Lavie CJ et al (2015) Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Int J Cardiol 179:279–287. https://doi.org/10.1016/j.ijcard.2014.11.101CrossRefPubMed

56.

Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M et al (2019) Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 171:685–694. https://doi.org/10.7326/M19-0291CrossRefPubMed

57.

De Caterina R, Husted S, Wallentin L et al (2013) Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 110:1087–1107. https://doi.org/10.1160/TH13-06-0443CrossRefPubMed

58.

Holmes DRJ, Doshi SK, Kar S et al (2015) Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 65:2614–2623. https://doi.org/10.1016/j.jacc.2015.04.025CrossRefPubMed

59.

Price MJ, Reddy VY, Valderrábano M et al (2015) Bleeding outcomes after left atrial appendage closure compared with long-term warfarin: a pooled, patient-level analysis of the WATCHMAN randomized trial experience. JACC Cardiovasc Interv 8:1925–1932. https://doi.org/10.1016/j.jcin.2015.08.035CrossRefPubMed

60.

Koniari I, Kounis NG, Tsigkas G, Hahalis G (2018) Device-associated thrombus formation after left atrial appendage occlusion. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv 92:E215CrossRef

61.

Reddy VY, Möbius-Winkler S, Miller MA et al (2013) Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 61:2551–2556. https://doi.org/10.1016/j.jacc.2013.03.035CrossRefPubMed

62.

Meier B, Blaauw Y, Khattab AA et al (2014) EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Eur Eur pacing, arrhythmias, Card Electrophysiol J Work groups Card pacing, arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol 16:1397–1416. https://doi.org/10.1093/europace/euu174CrossRef

63.

Santema BT, Kloosterman M, Van Gelder IC et al (2018) Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. Eur Heart J 39:3867–3875. https://doi.org/10.1093/eurheartj/ehy421CrossRefPubMed

64.

Christopoulos G, Graff-Radford J, Lopez CL et al (2020) Artificial intelligence-electrocardiography to predict incident atrial fibrillation: a population-based study. Circ Arrhythm Electrophysiol 13:e009355. https://doi.org/10.1161/CIRCEP.120.009355CrossRefPubMedPubMedCentral

65.

Khan MN, Jaïs P, Cummings J et al (2008) Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 359:1778–1785. https://doi.org/10.1056/NEJMoa0708234CrossRefPubMed

66.

Jones DG, Haldar SK, Hussain W et al (2013) A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 61:1894–1903. https://doi.org/10.1016/j.jacc.2013.01.069CrossRefPubMed

67.

Hunter RJ, Berriman TJ, Diab I et al (2014) A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 7:31–38. https://doi.org/10.1161/CIRCEP.113.000806CrossRefPubMed

68.

Elgendy AY, Mahmoud AN, Khan MS et al (2018) Meta-analysis comparing catheter-guided ablation versus conventional medical therapy for patients with atrial fibrillation and heart failure with reduced ejection fraction. Am J Cardiol 122:806–813. https://doi.org/10.1016/j.amjcard.2018.05.009CrossRefPubMed

69.

Machino-Ohtsuka T, Seo Y, Ishizu T et al (2019) Relationships between maintenance of sinus rhythm and clinical outcomes in patients with heart failure with preserved ejection fraction and atrial fibrillation. J Cardiol 74:235–244. https://doi.org/10.1016/j.jjcc.2019.02.014CrossRefPubMed

70.

Kelly JP, DeVore AD, Wu J et al (2019) Rhythm control versus rate control in patients with atrial fibrillation and heart failure with preserved ejection fraction: insights from get with the guidelines-heart failure. J Am Heart Assoc 8:e011560. https://doi.org/10.1161/JAHA.118.011560CrossRefPubMedPubMedCentral

Titel: Heart failure and atrial fibrillation: new concepts in pathophysiology, management, and future directions
verfasst von: Grigorios Tsigkas
Anastasios Apostolos
Stefanos Despotopoulos
Georgios Vasilagkos
Eleftherios Kallergis
Georgios Leventopoulos
Virginia Mplani
Periklis Davlouros
Publikationsdatum: 04.07.2021
Verlag: Springer US
Schlagwörter: ß-Blockers
Heart Failure
Atrial Fibrillation
Erschienen in: Heart Failure Reviews / Ausgabe 4/2022
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-021-10133-6

Neu im Fachgebiet Kardiologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Heart failure and atrial fibrillation: new concepts in pathophysiology, management, and future directions

Abstract

Neu im Fachgebiet Kardiologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Cognitive impairment in heart failure: clinical implications, tools of assessment, and therapeutic considerations

New antidiabetic therapy and HFpEF: light at the end of tunnel?

Ventricular non-compaction review

Multiple roles of cardiac macrophages in heart homeostasis and failure

The role of non-invasive imaging modalities in cardiac allograft vasculopathy: an updated focus on current evidences

Filamin C in cardiomyopathy: from physiological roles to DNA variants

Neu im Fachgebiet Kardiologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie